Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression
Tetra Pharm Technologies has reached a significant in developing its compound for appetite suppression, TPT0701, following the successful...
top of page
Browse by category
Search
Skye to develop nimacimab for the treatment of obesity by targeting the endocannabinoid system
Skye Bioscience, a pharmaceutical company developing drugs targeting the endocannabinoid system (ECS), has announced that it plans to...
Browse by tag
bottom of page